These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
208 related articles for article (PubMed ID: 28232379)
21. Late structural discontinuity after bioresorbable vascular scaffold implantation in patients with in-stent restenosis. Cuesta J; Antuña P; Bastante T; Alfonso F EuroIntervention; 2021 Jan; 16(13):1104-1105. PubMed ID: 31062695 [No Abstract] [Full Text] [Related]
22. Target lesion revascularisation of bioresorbable metal scaffolds: a case series study and literature review. Ortega-Paz L; Brugaletta S; Gomez-Lara J; Sanchis J; Fernández-Díaz JA; Artaiz-Urdaci M; Alfonso F; Garcia-Garcia HM; Sabaté M EuroIntervention; 2021 Jan; 16(13):1100-1103. PubMed ID: 31475905 [No Abstract] [Full Text] [Related]
23. Percutaneous coronary intervention: balloons, stents and scaffolds. Colleran R; Kastrati A Clin Res Cardiol; 2018 Aug; 107(Suppl 2):55-63. PubMed ID: 30039189 [TBL] [Abstract][Full Text] [Related]
24. From plumbers to vascular restorers: has the Promethean promise of bioresorbable coronary scaffolds yet to be fulfilled? Escaned J; van Royen N EuroIntervention; 2020 Jun; 16(2):e106-e108. PubMed ID: 32538789 [No Abstract] [Full Text] [Related]
25. A bioresorbable everolimus-eluting scaffold versus a metallic everolimus-eluting stent for ischaemic heart disease caused by de-novo native coronary artery lesions (ABSORB II): an interim 1-year analysis of clinical and procedural secondary outcomes from a randomised controlled trial. Serruys PW; Chevalier B; Dudek D; Cequier A; Carrié D; Iniguez A; Dominici M; van der Schaaf RJ; Haude M; Wasungu L; Veldhof S; Peng L; Staehr P; Grundeken MJ; Ishibashi Y; Garcia-Garcia HM; Onuma Y Lancet; 2015 Jan; 385(9962):43-54. PubMed ID: 25230593 [TBL] [Abstract][Full Text] [Related]
26. First serial assessment at 6 months and 2 years of the second generation of absorb everolimus-eluting bioresorbable vascular scaffold: a multi-imaging modality study. Ormiston JA; Serruys PW; Onuma Y; van Geuns RJ; de Bruyne B; Dudek D; Thuesen L; Smits PC; Chevalier B; McClean D; Koolen J; Windecker S; Whitbourn R; Meredith I; Dorange C; Veldhof S; Hebert KM; Rapoza R; Garcia-Garcia HM Circ Cardiovasc Interv; 2012 Oct; 5(5):620-32. PubMed ID: 23048057 [TBL] [Abstract][Full Text] [Related]
27. Procedural resources utilization and clinical outcomes with bioresorbable everolimus-eluting scaffolds and Pt-Cr everolimus-eluting stent with resorbable abluminal polymer in clinical practice. A randomized trial. de la Torre Hernandez JM; Garcia Camarero T; Lee DH; Sainz Laso F; Veiga Fernandez G; Pino T; Rubio S; Legarra P; Valdivia JR; Zueco Gil J Catheter Cardiovasc Interv; 2017 Aug; 90(2):E25-E30. PubMed ID: 27807948 [TBL] [Abstract][Full Text] [Related]
28. Mid- to long-term outcome of patients treated with everolimus-eluting bioresorbable vascular scaffolds: Data of the BVS registry Göttingen predominantly from ACS patients. Hellenkamp K; Becker A; Gabriel YD; Hasenfuß G; Hünlich M; Jacobshagen C; Schillinger W; Schroeter MR Int J Cardiol; 2017 May; 234():58-63. PubMed ID: 28258843 [TBL] [Abstract][Full Text] [Related]
29. Absorb bioresorbable vascular scaffold versus everolimus-eluting metallic stent in ST-segment elevation myocardial infarction: 1-year results of a propensity score matching comparison: the BVS-EXAMINATION Study (bioresorbable vascular scaffold-a clinical evaluation of everolimus eluting coronary stents in the treatment of patients with ST-segment elevation myocardial infarction). Brugaletta S; Gori T; Low AF; Tousek P; Pinar E; Gomez-Lara J; Scalone G; Schulz E; Chan MY; Kocka V; Hurtado J; Gomez-Hospital JA; Münzel T; Lee CH; Cequier A; Valdés M; Widimsky P; Serruys PW; Sabaté M JACC Cardiovasc Interv; 2015 Jan; 8(1 Pt B):189-197. PubMed ID: 25616924 [TBL] [Abstract][Full Text] [Related]